Accession Number: | 0001209191-21-049765 |
Date: | 2021-08-03 |
Issuer: | TENAYA THERAPEUTICS, INC. (TNYA) |
Original Submission Date: |
CASDIN PARTNERS MASTER FUND, L.P.
1350 AVENUE OF THE AMERICAS
SUITE 2600
NEW YORK, NY 10019
CASDIN PRIVATE GROWTH EQUITY FUND, L.P.
1350 AVENUE OF THE AMERICAS
SUITE 2600
NEW YORK, NY 94080
CASDIN CAPITAL, LLC
1350 AVENUE OF THE AMERICAS
SUITE 2600
NEW YORK, NY 10019
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
1350 AVENUE OF THE AMERICAS
SUITE 2600
NEW YORK, NY 10019
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-08-03 | C | 2,374,849 | a | $0.00 | 2,374,849 | indirect | ||
COMMON STOCK | 2021-08-03 | P | 850,000 | a | $15.00 | 3,224,849 | indirect | ||
COMMON STOCK | 2021-08-03 | C | 361,969 | a | $0.00 | 361,969 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
SERIES B PREFERRED STOCK | 0.0 | 2021-08-03 | deemed execution date | C | 2,012,880 (d) | common stock 2,012,880 | $0.00 | 0 | indirect | see footnotes | ||
SERIES C PREFERRED STOCK | 0.0 | 2021-08-03 | deemed execution date | C | 361,969 (d) | common stock 361,969 | $0.00 | 0 | indirect | see footnotes | ||
SERIES C PREFERRED STOCK | 0.0 | 2021-08-03 | deemed execution date | C | 361,969 (d) | common stock 361,969 | $0.00 | 0 | indirect | see footnotes |
ID | footnote |
---|---|
f1 | these shares are held directly by casdin partners master fund, l.p.(cpmf). |
f2 | casdin capital, llc is the investment advisor to cpmf and cpgef. casdin partners gp, llc is the general partner of cpmf. casdin private growth equity fund gp, llc is the general partner of cpgef. the reporting person is the managing member of casdin capital, llc, casdin partners gp, llc and casdin private growth equity fund gp, llc and may be deemed to have voting and investment power with respect to the shares. the reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
f3 | these shares are held directly by casdin private growth equity fund, l.p. (cpgef). |
f4 | each share of series a preferred stock, series b preferred stock and series c preferred stock automatically converted into one share of common stock immediately prior to the completion of the issuer's initial public offering, and had no expiration date. |